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Osmoregulation and renal effects of vasopressin in normal and mildly
hypertensive subjects. A 2-hr 0.85 M hypertonic saline infusion was
administered to ten normotensive volunteers and ten mildly hyperten-
sive subjects to compare in these two groups the osmoregulation of
vasopressin and the effect of this hormone on BP. No significant
alteration in BP was observed in either group, despite markedly
enhanced vasopressin levels. Significant positive correlations between
plasma vasopressin (AVP) and plasma osmolality (Posm) were demon-
strated in the controls (AVP = —70 + 0.25 Posm, r = 0.68, P < 0.0001)
and in the hypertensive group (AVP —46 + 0.16 Pom, r = 0.59, P <
0.0001). However, the vasopressin response to the osmotic stimulus
was buffered in the hypertensive subjects; the slope of the regression
line between plasma vasopressin and plasma osmolality was less steep
in hypertensive subjects than in normotensive subjects (0.16 vs. 0.25, P
<0.018). During the saline infusion the renal parameters were identical
in the two groups. Finally, in mild hypertension, the osmoregulation of
vasopressin was preserved but buffered and renal sensitivity to this
hormone was normal. An osmotically induced physiological increase in
vasopressin did not raise BP in either normotensive or mildly hyperten-
sive subjects.
Osmoregulation et effets rénaux de Ia vasopressine chez des sujets
normaux et modérément hypertendus. Une perfusion de 2 heures de
solute sale hypertonique a 0,85 M a éte administrée a dix volontaires
normotendus et dix sujets modérément hypertendus afin de comparer
dans ces deux groupes l'osmoregulation de Ia vasopressine et l'effet de
cette hormone sur Ia pression artérielle. Aucune alteration significative
de Ia pression artérielle n'a été observée dans chacun des groupes,
malgré des niveaux de vasopressine stimulés de facon marquee. Des
correlations positives significatives entre Ia vasopressine plasmatique
(AVP) et l'osmolalitd plasmatique (Pom) ont été démontrées chez les
contrôles (AVP = —70 + 0,25 POSm, r = 0,68, P < 0,0001) et dans le
groupe hypertendu (AVP = 46 + 0,16 POEm, r = 0,59, P < 0,0001).
Cependant, Ia reponse de Ia vasopressine au stimulus osmotique était
amortie chez les sujets hypertendus; Ia pente de Ia droite de regression
entre Ia vasopressine plasmatique et l'osmolalité plasmatique était
moms forte chez les sujets hypertendus que chez les sujects normoten-
dus (0,16 contre 0,25, P < 0,018). Pendant Ia perfusion de solute sale,
les paramètres rénaux étaient identiques dans les deux groupes. En fin
de compte, dans l'hypertension modérée, l'osmoregulation de Ia Va-
sopressine était préservée mais amortie et Ia sensibilité rénale a cette
hormone était normale. Une augmentation physiologique induite de
facon osmotique de Ia vasopressine n'a pas augmenté Ia pression
artérielle chez les normotendus ni chez les sujets hypertendus modérés.
Vasopressin is a potent vasoconstrictor peptide [1] that
participates in blood pressure (BP) homeostasis in several
conditions including dehydration [21 and hemorrhage [3]. The
results of experiments in the dog conducted by Montani et al [41
indicate that vasopressin levels within the physiological range
produce significant hemodynamic alterations, including a BP
increase when the baroreceptor reflex is altered. Several works
suggest that this hormone is involved in the pathogenesis of
certain types of experimental hypertension in animals [5, 6].
Recently, enhanced plasma and urinary vasopressin levels were
found in human hypertension, especially in the severe forms of
the disease [7—91. So far, however, insufficient data make it
impossible to know whether these increased vasopressin levels
should be considered as a cause or a consequence of the
disease.
With the help of sensitive radioimmunoassay techniques,
Robertson [101 demonstrated that vasopressin secretion is
under the control of a very sensitive osmoregulation, that is,
hemodynamic factors can physiologically modulate the osmo-
regulation of vasopressin and consequently alter the relation-
ship between vasopressin secretion and plasma osmolality.
The present work was undertaken to explore vasopressin
osmoregulation in human hypertension with special reference
to the influence of the BP level on such osmoregulation. We
also tried to find out whether physiological increases in the
vasopressin level could modify BP in humans. Lastly, we
attempted to detect any alterations in renal sensitivity to
vasopressin occurring in mild and recent human hypertension.
Methods
Ten healthy volunteers of normal weight (nine males; age
range, 22 to 42 years; mean, 27) and ten recent mild essential
hypertensive subjects of normal weight (seven males; age
range, 22 to 52; mean, 34) were included in the study protocol to
which they gave their informed consent. For the hypertensive
patients, who were investigated after 3 days in the hospital, the
diagnosis of essential hypertension was based on physical
examination, laboratory tests including plasma potassium, re-
nm activity, and aldosterone and urinary vanillyl mandelic acid
assays, and intravenous pyelography. Their Sokolow index was
18 to 35 mm (mean, 29), creatinine clearance was 86 to 156
ml min' (mean, 114), and the ocular fundi was stage 0 in five
patients, and stage 1 in five patients. Their hypertension had
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been detected from I month to 5 years previously (mean, 2
years). None smoked. None had taken prescribed or other
drugs, and their diet included 6 g NaCI/day and water ad libitum
for 3 days before the test. After overnight dehydration, patients
were weighed and remained fasting and recumbent from 8 to 12
hr. The bladder was emptied at 8 hr for completion of 24-hr
urine collection prior to the test.
From 8:30 A.M. to 12 P.M. BP and heart rate were recorded
every 5 mm with an automatic device (Sentry ASD 4000, ASD
Inc., Costa Messa, California); the BP cuff was applied to the
right arm. An indwelling catheter was inserted at 8 A.M. in an
antecubital vein and was kept patent with a stylet (Cathion IV
Jelco Laboratories, Raritan, New Jersey). For determination of
hematocrit and plasma osmolality, sodium, potassium, creati-
nine, and vasopressin, blood samples were drawn into chilled
heparinized glass tubes (dry heparin, 100 1U 10 m1') at 8:30
and 9A.M., then at 20-mm intervals until 11 A.M., and finally at
11:30 A.M. and 12P.M. Additional samples were drawn at 9 and
11 A.M. for determination of plasma renin activity, aldosterone,
and cortisol. An infusion of 0.85 M saline solution was started at
9 A.M. into the other antecubital vein at the rate of 0.06
ml kg' min for 2 hr, using a rotary pump (Infusomat,
Braun, West Germany). For each blood sample, 3 aliquots of
whole blood were drawn into heparinized capillary tubes to
measure hematocrit (Red-tip Lancer, St. Louis, Missouri). The
remaining blood was immediately centrifuged at 4°C, and
osmolality was determined on three fresh plasma samples. The
others were deep-frozen for measurement, by previously de-
scribed radioimmunoassay techniques, of plasma vasopressin
(AVP) [11, 12], renin activity (PRA) [13], aldosterone (PA) [14],
and cortisol (PC) [15]. The time at which subjects experienced
thirst was noted. At 12 P.M. when the test ended, patients
voided; we measured urinary volume, osmolality, sodium,
potassium, creatinine and vasopressin in this 4-hr urine sam-
pling [12, 16].
Because vasopressin values are higher in urine than plasma,
the antibody we used for the radioimmunoassay of urinary
vasopressin was less sensitive than the one used to measure
plasma vasopressin. However, both antibodies equally recog-
nized the cyclic moiety of the vasopressin molecule (100%
cross-reactivity with lysine vasopressin, less than 0.1% cross-
reactivity with oxytocin and arginine vasotocin). For 24 differ-
ent urine specimens containing 20 to 1600 pg of vasopressin, a
comparison of the results for the two antibodies revealed
identical values (y = 1.0 lx + 6.85, r = 0.99 P < 0.0001) [12].
Results are expressed as means SEM. Mean arterial blood
pressure (MAP) was calculated by adding one-third pulse
pressure to the diastolic pressure. Statistical calculations were
carried out by using the Statistic Manual of the Prophet System
from the National Institutes of Health [17]. Two-way variance
analysis, Dunnett's test, least squares method, and covariance
analysis for comparison of slopes were used. P < 0.05 was
considered statistically significant.
Results
In the basal state, the groups of patients and subjects were
comparable for age (27 2 vs. 34 3 years), weight (68 3 vs.
66 3 kg), and all the blood parameters recorded at 9 A.M. The
following levels were respectively found in healthy subjects and
patients: hematocrit, 45 1 vs. 44 1%; plasma sodium, 141
1 vs. 140 1 mmoles liter', osmolality, 289 1 vs. 289 1
88
12.00
Time, hours
Fig. 1. Mean arterial BP recorded in both groups during saline infusion.
mOsm kg—'; proteins, 69 1 vs. 68 1 g liter'; creatinine,
85 2 vs. 85 5 mmoles liter'; potassium, 4.2 0.1 vs. 4.4
0.1 mmoles liter'; vasopressin, 1.30 0.30 vs. 0.83 0.15
pmoles liteC'; renin activity, 1.22 0.28 vs. 0.75 0.15
nmoles . liter' hr'; aldosterone, 308 53 vs. 226 58
pmoles liter'; and cortisol, 413 35 vs. 383 56 nmoles li-
ter'. For urinary parameters, basal values for the 24-hr urine
sample preceding the test were similar in both groups for
sodium (135 11 vs. 116 16 mmoles), potassium (65 5 vs.
67 6 mmoles), and AVP (46 6 vs. 42 7 pmoles)
excretions.
Finally, basal mean arterial blood pressure (average of the
seven values recorded between 8:30 and 9 A.M.) was significant-
ly higher in the hypertensive group (102 1 vs. 93 1 mm Hg,
P < 0.001), and the heart rate was similar in both groups (67 vs.
71 beats min').
During the 2-hr saline infusion, both groups received the
same amount of sodium (418 20 vs. 406 19 mmoles).
Significant identical increases in plasma sodium and osmolality
were noted, averaging respectively 8 1 mmoles liter' and
17 1 mOsm kg' for the normotensive controls (NT) and 8
1 mmoles . liter' and 16 1 mOsm kg' for the hyperten-
sive group (HT). Concomitant, significant drops in hematocrit
and protein values occurred averaging, respectively, 4 1%
and 7 lg liter' for NT, 5 1% and 8 1 g liter' forHT.
The time at which thirst was experienced was identical in
both groups (10.00 0.28 hr vs. 10.00 0.48 hr) and so were
the corresponding plasma osmolalities (298 1 vs. 296 1
mOsm . kg').
During the entire test, mean arterial blood pressure remained
unchanged in the NT group, varying between 87 3 and 95 3
mm Hg. In the HT group, a slight nonsignificant increase from
102 3 to 107 6 mm Hg occurred at the end of the saline
infusion (Fig. 1). No variation in heart rate was recorded during
the whole test in either group. Both groups tolerated the study
well and in particular experienced no pain or nausea.
Plasma vasopressin rose significantly in both groups, attain-
ing 5.70 0.92 pmoles liter' in the NT group at 10.4 hr and
4.50 0.60 pmoles liter' at 11 hr in the HT group. However,
the value of the area under the curve for plasma vasopressin
plotted versus time was significantly lower in the HT than in the
NT group (594 70 vs. 810 105 pmoles liter' min', P <
0.05) (Fig. 2).
0.85 M Saline infusion
006 m/kg.min' J
Mean
arterial
blood
pressure
[mm Hg]
108
98
Control
9.00 10.00 11.00
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Linear regression analysis of plasma osmolality versus plas-
ma vasopressin was applied to each individual infusion of
hypertonic saline and to the pool data from each group. The
relation was statistically significant in all patients and control
subjects (Table 1). Similar conclusions can be drawn when
Normotensive group Hypertensive group
Subject X Correlation X Correlation
no. Intercept Slope coefficient Intercept Slope coefficient
1 281 0.35 0.75 283 0.20 0.88
2 280 0.12 0.9! 281 0.19 0.84
3 283 0.39 0.83 287 0.22 0.72
4 287 0.26 0.97 281 0.11 0.61
5 274 0.08 0.62 288 0.10 0.96
6 287 0.32 0.89 275 0.08 0.91
7 291 0.44 0.86 284 0.20 0.72
8 288 0.29 0.88 280 0.25 0.86
9 274 0.10 0.70 285 0.25 0.85
10 286 0.22 0.89 289 0.47 0.86
Linear regression
AVP = 70 + 0.25 P0 AVP = 46 + 0.16 POsm
r = 0.68, P < 0.0001 r = 0.59, P < 0.0001
Osmotic threshold = Osmotic threshold =
283 mOsm/kg 281 mOsm/kg
Semilogarithmic regression
L0gAVP= —23 + L0gAVP= —19+
0.082 P0,,, 0.066 P0,,,
r = 0.72, P < 0.0001 r = 0.64, P < 0.0001
Osmotic threshold = Osmotic threshold =
286 mOsrn/kg 286 mOsm/kg
studying the relation between plasma osmolality and logarithmi-
cally transformed plasma vasopressin values. The correlation
coefficients were even better with log AVP values than with the
AVP values (Table 1).
Similarly, plasma renin activity, aldosterone, and cortisol
dropped at the end of the saline infusion in both groups (Table
2).
Urine samples collected from both groups between 8 A.M.
and 12 P.M. displayed similar values in volume, osmolar clear-
ance, free water clearance, creatinine clearance, and AVP
clearance (Table 3); the averaged values of plasma AVP and
plasma osmolality levels measured throughout the 4-hr period
were used to calculate clearances. Finally, the amount of
sodium excreted during the saline infusion period was identical
in both groups.
Discussion
The present results confirm that, in normal subjects, taken
either individually, or as a group, a saline infusion at a constant
rate causes closely linked increases in plasma osmolality and
T0 plasma vasopressin levels. Our data agree in a broad sense with
the original theory of Verney, further confirmed by Robertson
[10] and others [12] with the aid of sensitive radioimmunoas-
says. In particular the osmotic threshold for AVP release
calculated from the linear regression between plasma osmolali-
ty and plasma vasopressin in our group of normal subjects
(plasma osmolality = 283 mOsm/kg) is very similar to that
reported by Baylis and Robertson [18] using the same protocol
(plasma osmolality = 284 mOsmlkg) or by Ganguly and Robert-
son [191 using a standard hypertonic saline infusion (plasma
osmolality = 284 mOsm/kg).
In both our groups, the log-linear relationship gave a better
coefficient of correlation between plasma vasopressin and plas-
ma osmolality than the linear relationshin ic rdredv rptnrfd
Proteins
gIiter1 0.85 M Saline infusion
j [ 006 mI•kg'min-1 ]
Table 1. Regression analysis of plasma vasopressin versus plasma
osmolality in normotensive volunteers and hypertensive patients
1
— Control
-- Hypertensive
*
*
*
* *
* *
* **
*
Plasma vasopressin[pmo/esIiter —
*
*
Control
*
*
72
66
60
6
3
0
308
298
288
Fig. 2. Alterations in plasma proteins, osmolaliiy, and vasopressin
induced by hypertonic saline infusion. Asterisks indicate the following:
*, the value is significantly different from the control value, P < 0.05;
°', idem, P < 0.01; ***, idem, P < 0.001.
* *
* * * *
* * * *
* *
*
Hypertensive
Plasma osmotality
[mOsmkg 1J
4'
"C
'p
Hypertensive
9.00 10.00 11.00
Time, hours
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Table 2. Alterations in plasma renin activity, plasma aldosterone, and
plasma cortisol induced by hypertonic saline infusion in the
normotensive group (NT) and hypertensive patients (HT)
9 A.M. 11 A.M.
Plasma renin activity
(nmoles/liter/hr)
NT
HT
1.22 + 0.28
0.75 + 0.15
0.44 + 0.08k
0.35 + 0.08k
Plasma aldosterone
(pmoles/liter)
NT
HT
308 + 53226 + 58 171 + 27131 + 36a
Plasma cortjsol
(nmoles/liter)
NT
HT
413 + 31383 + 56 237 + 33a309 + 48a
This value is significantly lower than the corresponding basal value.
by Weitzman and Fisher in the sheep [20]. However, one
should not forget the comments of Rodbard and Munson 121]
who pointed out that "there is no simple statistical significance
test to evaluate whether the experimental model gives a signifi-
cantly better fit than the threshold model." Further, Hammer,
Ladefoged, and Olgaard [22] demonstrated that the relationship
between AVP and osmolality depends on the hydration state,
which in turn "can influence the secretion rate and/or the
metabolic clearance rate and thereby the relationship." The
best type of regression calculation is therefore still an open
question.
Despite the significant increase in vasopressin induced by the
hypertonic saline infusion, we observed no consistent alteration
in BP in the control group as well as in the hypertensive group.
Three other investigations used the same protocol in healthy
volunteers: One, involving automatic BP monitoring at 2-mm
intervals with a cuff applied to the thigh, reported a significant
rise of 15 4 mm Hg in mean arterial pressure toward the end
of the infusion [18]. The second, in which BP was recorded at 5-
mm intervals according to the same method as in the study just
cited, reported no alteration in this parameter [23]. In the third
of these investigations, which failed to reveal any relationship
between plasma vasopressin and plasma osmolality, no com-
ment about BP was made [24]. These discrepancies in BP
alterations during saline infusion in normal subjects could be
due to several factors, one being the frequency of the BP
recordings. In our experience, noninvasive BP monitoring at 2-
mm intervals for 3 hr with an automatic device can cause a local
discomfort generating an artefactual increase in BP.
In the present report, the plasma and urinary vasopressin
levels recorded during the basal state in the group of hyperten-
sive patients were within the normal range, confirming previous
work from our own or other laboratories [7, 8, 19]. The
exploration of this group of ten recent mild hyptertensive
patients with normal basal vasopressin values seems to be
appropriate for detection of subtle alterations in vasopressin in
the early stages of hypertension and thus for investigating
whether vasopressin is involved in the pathogeny of BP eleva-
tion in essential hypertension.
Several conclusions can be drawn from the exploration of our
hypertensive group: The osmoregulation of vasopressin is pre-
served in mild human hypertension, as illustrated by the
significant relationship we found between plasma osmolality
and plasma vasopressin in each patient and in the hypertensive
group as a whole. However, Robertson, Shelton, and Athar [25]
showed that a pharmacologically induced BP reduction affected
Table 3. Urinary parameters measured in both groups during the 4-hr
test
Normotensive
group
Hypertensive
group
Urinary output 2.78 + 0.44 2.61 + 0.28
mi/mm
Urinary osmolality 724 + 47 634 + 35
mOsm/kg
Sodium excretion 0.57 + 0.08 0.55 + 0.06
mmoles/min
Potassium excretion 0.16 + 0.02 0.16 + 0.02
mmoies/min
Osmolar clearance 6.20 + 0.74 5.37 + 0.41
mi/mm
Free water clearance —3.41 + 0.37 —2.76 + 0.22
mi/mm
Creatinine clearance 178 + 10 169 + 14
mi/mm
AVP excretion 0.31 + 0.06 0.31 + 0.05
pmoies/mmn
AVP clearance 85 + 12 124 + 30
mi/mm
AVP clearance X 100 47 + 6 74 + 14
Creatinine clearance
the osmoregulation of vasopressin. This author proposed a
graph depicting the influence of hemodynamic factors on the
relationship between plasma osmolality and plasma vasopres-
sin. According to this scheme, an increase in BP causes a
rightward shift of the regression line, which is characterized by
a reduction of its slope, that is, a higher plasma osmolality value
is necessary in hypertensive than in normotensive subjects to
obtain a similar given plasma vasopressin level. In accordance
with this hypothesis, we found that in our hypertensive group
the slope of the regression line was significantly less steep than
the slope for the normotensive group. This buffered response of
plasma vasopressin to the osmotic stimulus in mild hyperten-
sion is also suggested by the significant reduction in the area
under the curve for plasma vasopressin plotted versus time in
the hypertensive group, compared to the normotensive con-
trols. In this connection, De Lima et al [26] reported that the
volume-dependent vasopressin secretion was blunted in pa-
tients with benign low renin hypertension.
At variance with the aforementioned results are those report-
ed by Ganguly and Robertson [19] who found that the slope of
the linear regression of plasma vasopressin versus plasma
osmolality was not modified in a group of 15 patients with
essential hypertension, compared to a group of 11 normal
subjects. Several factors can explain these discrepancies. Ac-
cording to the scheme proposed by Robertson, different levels
of BP in Ganguly's group and in our hypertensive group can
modulate the relationship between plasma vasopressin and
plasma osmolality. Among the other mechanisms different rates
and concentrations of saline infusions and different states of
hydration can take place.
Plasma osmolalities at which thirst was first experienced
were identical in both groups. Although this subjective sensa-
tion is difficult to assess, it did not seem to alter in our mildly
hypertensive patients, as occurs in severe hypertension.
It can be deducted from our study that in recent mild human
hypertension renal sensitivity to vasopressin is preserved.
Designed to explore glomerular filtration and tubular and col-
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lecting duct exchanges, all the assessed urinary parameters
behaved similarly in both groups during the saline infusion. In
particular, the absence of any difference in urinary output,
urinary osmolality, and free water clearance confirms that renal
sensitivity to vasopressin was preserved. Despite the different
BP levels, the identical sodium excretion in both groups can be
explained by the pressure-natriuresis phenomenon formulated
by Guyton [27], according to whom a higher BP regimen is
necessary in hypertensfon than in normotension to excrete a
given sodium load.
No significant increase in BP in either hypertensive or normal
groups occurred, despite the significant increase in plasma
vasopressin induced by saline infusion. This suggests that either
the vasopressin increment was insufficient to provoke an alter-
ation in BP, and/or that counter-regulating systems operate
perfectly and buffer the potent vascular effect of vasopressin,
with a resulting unchanged BP. Among these systems, the shut-
off of the renin-angiotensin-aldosterone system induced by
saline infusion certainly favors the constancy of BP.
Finally, our results show that osmoregulation of vasopressin
persists in recent mild human hypertension. However, a buff-
ered vasopressin response to the osmotic stimulus was ob-
served, which might have been due to interference of the higher
BP regimen with the osmotic stimulus. The renal sensitivity to
vasopressin was preserved in these patients. The absence of
any BP increase when vasopressin was physiologically stimu-
lated argues against the possibility that this hormone is directly
implicated in the pathogeny of recent mild essential
hypertension.
Reprint requests to Dr. M. Thibonnier, Division of Clinical Pharma-
cology and Experimental Therapeutics, HSE 1462, University of Cali-
fornia, San Francisco, San Francisco, Cal jfornia 94143, USA
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